open access

Vol 83, No 1 (2015)
REVIEWS
Submitted: 2015-01-08
Accepted: 2015-01-08
Get Citation

New dry powder inhalers

Andrzej Emeryk, Michał Pirożyński
DOI: 10.5603/PiAP.2015.0012
·
Pneumonol Alergol Pol 2015;83(1):83-87.

open access

Vol 83, No 1 (2015)
REVIEWS
Submitted: 2015-01-08
Accepted: 2015-01-08

Abstract

The most recently approved DPI’s — Ellipta™ and NEXThaler® are the most modern inhalers on the market. Both are flow independent in the physiological range of flows seen in patients with asthma and/or COPD. Both require three actions (open-load -inhaler) for a successful inhalation. The Ellipta™ inhaler is the first DPI, which enables simultaneous delivery of two compounds without need for co-formulation. NEXThaler® is the only DPI on the market delivering extra fine aerosol (MMAD < 2 μm) of a combined inhalation product of inhaled corticosteroid and long-action b2-agonist. Both have been approved world wide for products used in treatment of asthma and COPD.

Abstract

The most recently approved DPI’s — Ellipta™ and NEXThaler® are the most modern inhalers on the market. Both are flow independent in the physiological range of flows seen in patients with asthma and/or COPD. Both require three actions (open-load -inhaler) for a successful inhalation. The Ellipta™ inhaler is the first DPI, which enables simultaneous delivery of two compounds without need for co-formulation. NEXThaler® is the only DPI on the market delivering extra fine aerosol (MMAD < 2 μm) of a combined inhalation product of inhaled corticosteroid and long-action b2-agonist. Both have been approved world wide for products used in treatment of asthma and COPD.

Get Citation

Keywords

dry powder inhaler (DPI), Ellipta™, NEXThaler®

About this article
Title

New dry powder inhalers

Journal

Advances in Respiratory Medicine

Issue

Vol 83, No 1 (2015)

Pages

83-87

DOI

10.5603/PiAP.2015.0012

Bibliographic record

Pneumonol Alergol Pol 2015;83(1):83-87.

Keywords

dry powder inhaler (DPI)
Ellipta™
NEXThaler®

Authors

Andrzej Emeryk
Michał Pirożyński

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl